185 related articles for article (PubMed ID: 18522312)
41. Parents' attitudes toward school-based hepatitis B vaccination of their children.
Woodruff BA; Unti L; Coyle K; Boyer-Chuanroong L
Pediatrics; 1996 Sep; 98(3 Pt 1):410-3. PubMed ID: 8784365
[TBL] [Abstract][Full Text] [Related]
42. Acceptance and compliance with postpartum human papillomavirus vaccination.
Wright JD; Govindappagari S; Pawar N; Cleary K; Burke WM; Devine PC; Lu YS; Tsai WY; Lewin SN; Herzog TJ
Obstet Gynecol; 2012 Oct; 120(4):771-82. PubMed ID: 22996094
[TBL] [Abstract][Full Text] [Related]
43. Mothers' screening histories influence daughters' vaccination uptake: an analysis of linked cervical screening and human papillomavirus vaccination records in the North West of England.
Spencer Nee Pilkington AM; Brabin L; Verma A; Roberts SA
Eur J Cancer; 2013 Apr; 49(6):1264-72. PubMed ID: 23290788
[TBL] [Abstract][Full Text] [Related]
44. Determinants of vaccination coverage in rural Nigeria.
Odusanya OO; Alufohai EF; Meurice FP; Ahonkhai VI
BMC Public Health; 2008 Nov; 8():381. PubMed ID: 18986544
[TBL] [Abstract][Full Text] [Related]
45. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2003 to 2006.
Menzies R; Turnour C; Chiu C; McIntyre P
Commun Dis Intell Q Rep; 2008 Jun; 32 Suppl():S2-67. PubMed ID: 18711998
[TBL] [Abstract][Full Text] [Related]
46. Eligibility and willingness of first-year students entering university to participate in a HPV vaccination catch-up program.
Mehu-Parant F; Rouzier R; Soulat JM; Parant O
Eur J Obstet Gynecol Reprod Biol; 2010 Feb; 148(2):186-90. PubMed ID: 19926199
[TBL] [Abstract][Full Text] [Related]
47. Early lessons learned from extramural school programs that offer HPV vaccine.
Hayes KA; Entzel P; Berger W; Caskey RN; Shlay JC; Stubbs BW; Smith JS; Brewer NT
J Sch Health; 2013 Feb; 83(2):119-26. PubMed ID: 23331272
[TBL] [Abstract][Full Text] [Related]
48. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age.
Vesikari T; Van Damme P; Lindblad N; Pfletschinger U; Radley D; Ryan D; Vuocolo S; Haupt RM; Guris D
Pediatr Infect Dis J; 2010 Apr; 29(4):314-8. PubMed ID: 19952980
[TBL] [Abstract][Full Text] [Related]
49. The human papillomavirus vaccines.
Ljubojević S
Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
[TBL] [Abstract][Full Text] [Related]
50. Factors associated with parental intentions for male human papillomavirus vaccination: results of a national survey.
Dempsey AF; Butchart A; Singer D; Clark S; Davis M
Sex Transm Dis; 2011 Aug; 38(8):769-76. PubMed ID: 21336230
[TBL] [Abstract][Full Text] [Related]
51. Immunisation coverage annual report, 2011.
Hull BP; Dey A; Menzies RI; Brotherton JM; McIntyre PB
Commun Dis Intell Q Rep; 2013 Dec; 37(4):E291-312. PubMed ID: 24882234
[TBL] [Abstract][Full Text] [Related]
52. [Serological study carried out in Cambodia during a tetanus vaccination in adults].
Schlumberger M; Yvonnet B; Que HV; Chhem DB; Saliou P; Le Tu TC; Glaziou P
Bull Soc Pathol Exot; 2008 Feb; 101(1):36-42. PubMed ID: 18432006
[TBL] [Abstract][Full Text] [Related]
53. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
[TBL] [Abstract][Full Text] [Related]
54. Parental acceptance of a mandatory human papillomavirus (HPV) vaccination program.
Ferris D; Horn L; Waller JL
J Am Board Fam Med; 2010; 23(2):220-9. PubMed ID: 20207933
[TBL] [Abstract][Full Text] [Related]
55. The association between having a medical home and vaccination coverage among children eligible for the vaccines for children program.
Smith PJ; Santoli JM; Chu SY; Ochoa DQ; Rodewald LE
Pediatrics; 2005 Jul; 116(1):130-9. PubMed ID: 15995043
[TBL] [Abstract][Full Text] [Related]
56. Provider perceptions of barriers and facilitators of HPV vaccination in a high-risk community.
Javanbakht M; Stahlman S; Walker S; Gottlieb S; Markowitz L; Liddon N; Plant A; Guerry S
Vaccine; 2012 Jun; 30(30):4511-6. PubMed ID: 22561142
[TBL] [Abstract][Full Text] [Related]
57. Adolescent vaccination: coverage achieved by ages 13-15 years, and vaccinations received as recommended during ages 11-12 years, National Health Interview Survey 1997-2003.
McCauley MM; Stokley S; Stevenson J; Fishbein DB
J Adolesc Health; 2008 Dec; 43(6):540-7. PubMed ID: 19027641
[TBL] [Abstract][Full Text] [Related]
58. The cost-effectiveness of male HPV vaccination in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
[TBL] [Abstract][Full Text] [Related]
59. Human papillomavirus and cervical cancer: Gardasil vaccination status and knowledge amongst a nationally representative sample of Australian secondary school students.
Agius PA; Pitts MK; Smith AM; Mitchell A
Vaccine; 2010 Jun; 28(27):4416-22. PubMed ID: 20434543
[TBL] [Abstract][Full Text] [Related]
60. [Immunisation rates of routine vaccinations for school starters as a quantitative measure in the vaccination behaviour].
Stich HL; Beblo F
Gesundheitswesen; 2001 Dec; 63(12):748-54. PubMed ID: 11735067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
